Senhwa Biosciences, Inc. (6492) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Senhwa Biosciences, Inc. stock TWD 13.65, price TWD 28.65, that is 52.4% below the price, quality 48 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Senhwa Biosciences, Inc.
6492 · TWOFar too expensive (fair value 52% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 28.65 TWD – 203.50 TWD · fair‑value band 10.24 TWD – 17.06 TWD · the 28.65 TWD price screens above the 13.65 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Senhwa Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients.
Show moreShow less
The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma.
It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.
Stock analysis
Senhwa Biosciences, Inc. (6492) currently trades at 28.65 TWD, while our estimate is 13.65 TWD, 52% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 10.24 TWD (bear) to 17.06 TWD (bull), the price of 28.65 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Senhwa Biosciences, Inc. reported revenue of 1.1M TWD in FY2025 versus 550K TWD in FY2021, a compound +18.1%/yr. Reported net income was −265M TWD in FY2025.
Key figures
Market cap 3.4B TWD (≈ $102M) Micro · EPS (TTM) −3.22 TWD · Return on equity −39.0% · Return on assets (EBIT) −24.8% (5-year average) · Operating margin −35,328% · Revenue (TTM) 1.1M TWD · Revenue growth (YoY) −4.0% · Free cash flow −249M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 56% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −52%, 6492 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Senhwa Biosciences, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 6492 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 6492 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 6492 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 6492 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 6492 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 6492 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 6492 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 6492 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 6492 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 6492 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Senhwa Biosciences, Inc. (6492) overvalued or undervalued?
What is the fair value of 6492?
What is the quality score of 6492?
What is the price target for Senhwa Biosciences, Inc. (6492)?
What is the Senhwa Biosciences, Inc. stock forecast for 2026?
What is the revenue of Senhwa Biosciences, Inc. (6492)?
What is the intrinsic value of Senhwa Biosciences, Inc. (6492)?
Is Senhwa Biosciences, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 6492?
How much is Senhwa Biosciences, Inc. worth?
What do the bullish and bearish scenarios say about 6492?
How solid is the balance sheet of Senhwa Biosciences, Inc. (6492)?
How far is 6492 from its 52-week high?
Which stocks are comparable to Senhwa Biosciences, Inc.?
Is Senhwa Biosciences, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Senhwa Biosciences, Inc. (6492)?
What should I pay attention to with Senhwa Biosciences, Inc. right now?
Key figures of Senhwa Biosciences, Inc.
How large is the market capitalisation of Senhwa Biosciences, Inc. (6492)?
What are the earnings per share of Senhwa Biosciences, Inc. (6492)?
What is the return on equity of Senhwa Biosciences, Inc. (6492)?
What is the EBIT return on assets of Senhwa Biosciences, Inc. (6492)?
What is the operating margin of Senhwa Biosciences, Inc. (6492)?
How fast is revenue growing at Senhwa Biosciences, Inc. (6492)?
How much free cash flow does Senhwa Biosciences, Inc. (6492) generate?
Watch Senhwa Biosciences, Inc. in the live analysis
One click puts Senhwa Biosciences, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.